Inhibrx, Inc. (NASDAQ:INBX) Short Interest Up 5.8% in November

Inhibrx, Inc. (NASDAQ:INBX - Get Free Report) was the target of a significant increase in short interest in November. As of November 30th, there was short interest totalling 1,090,000 shares, an increase of 5.8% from the November 15th total of 1,030,000 shares. Currently, 11.0% of the company's shares are short sold. Based on an average daily trading volume, of 84,700 shares, the days-to-cover ratio is presently 12.9 days.

Insider Activity

In other Inhibrx news, Director Jon Faiz Kayyem purchased 69,686 shares of the firm's stock in a transaction on Tuesday, November 19th. The shares were purchased at an average cost of $14.23 per share, with a total value of $991,631.78. Following the purchase, the director now owns 51,093 shares in the company, valued at approximately $727,053.39. This represents a -374.80 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 22.20% of the company's stock.

Inhibrx Trading Down 0.4 %

Shares of INBX stock traded down $0.06 during trading hours on Monday, hitting $14.56. 42,160 shares of the company were exchanged, compared to its average volume of 130,945. Inhibrx has a 1 year low of $10.80 and a 1 year high of $18.95. The firm has a fifty day moving average of $15.36 and a 200 day moving average of $14.80.

About Inhibrx

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.